Wednesday , May 18 2022

Increase progress: along with the creation of a cartilage regenerating drug – 02/12/2018



[ad_1]

New Experimental Strategy Developed by the Massachusetts Institute of Technology (MIT) in Cambridge (United States)After entering the cartilage of the article, it gives it an anti-arterial medication and regenerates it. Beforehand, it is supposed to be tested in rats To get a breakthrough in the progression of the progression of this disease, there is now no cure.

Osteoarthritis is a progressive degeneration of cartilage joint due to aging or wounds. It causes this pathology 300 million people Everywhere in the world, and not the reverse gear, as it is a cartilage, can not be rebuilt. While therapy to relieve symptoms of osteoarthritis, there is currently no progress in slowing down this treatment. If the pharmacological treatment is not sufficient, patients may have an effect on the introduction of a prosthesis of a damaged joint, a risk and definitely free procedure.

One of the main obstacles is that the drug is very difficult to access the cartilage. Most seizures are removed before an effect or can not penetrate into the cartilage, the cells that produce it -condrocytes- are found so that they can not function.

Researchers at the MIT have sought a strategy to overcome this obstacle. They have designed a nano-carrier: a molecule that acts as a vehicle capable of penetrating the cartilage and placing a conducting drug. It forms a spherical component that binds this molecule, and thus connects the drug to the branch structure, with a positive electric charge and the PEG compound.

as cartilage charge is negative, the positive charge of the nanocarite retains the fabric. PEG, however, breaks through the cartilage and reaches condrocytes.

Fever study of Knee Arthritis by FIFP. They play three former football players

Fever study of Knee Arthritis by FIFP. They play three former football players

According to a report published in Science Translational Medicine, scientists added a drug called IGF-1, stimulating cartilage production and condensation and growth. To test the strategy, they nicknamed the drug drug After injuries in the arthritis of the knee joints. The treatment reduced the appearance of cartilage degeneration, inflammation and osteoarthritis. Compared with IGF-1 injection, in combination with nano-activation, ten of them had reached drug life in the joints. Also, this In thirty days, the cartilage was concentrated efficiently, so it would be enough for a two to three month period.

On the other hand, the researchers Cartilage beef detects this strategy through a drug that uses more than a millimeter tissue, a scale similar to human joints.

Diego Maradona suffers from osteoarthritis.

Diego Maradona suffers from osteoarthritis.

Nano-carriers could be able to deal with other drugs and treat arthritis associated with aging. Before testing people, authors should also try on other larger animals, with more similarities to humans.

"The research is very interesting," says Dr. Josep Verges and the President of the International Research Exhibition Foundation (OAFI). According to Verges, If it was applied to people and it was effective in rats, the new strategy could improve the quality of life of patients, one or two months of injection would be enough. "However, you should see that it is confirmed in clinical trials," says Verges, in order to be commercially available for a therapeutic strategy between four and eight years.

Source: La Vanguardia

[ad_2]
Source link